The assessment, and glucagon-like peptide-2 modulation, of intestinal absorption and function.
The treatment of patients with short bowel syndrome is hampered by a lack of treatment and measurement methods. This article reviews our evolving understanding of the role of glucagon-like peptide 2 (GLP-2) in controlling the adaptive process. The ability of the remnant intestine to produce GLP-2 appears to be predictive of the adaptive process; exogenous GLP-2 may be a therapy to augment adaptation. Strategies for monitoring patients, including conventional means, such as anthropomorphic measurements, plasma levels of specific nutrients, and vitamins and radiological contrast studies are reviewed. Investigational methods, such as nutrient balance studies, plasma citrulline levels, and the absorption of inert sugars (3-0 methyl glucose, mannitol, and lactulose) are discussed with the evidence to support their use.
Sigalet
David L
DL
Alberta Children's Hospital Intestinal Rehabilitation Program, Alberta Children's Hospital and University of Calgary, Calgary, Alberta, Canada. Sigalet@ucalgary.ca
Lam
Viona
V
Boctor
Dana
D
D000222:Adaptation, Physiological; D015415:Biomarkers / Q000378:metabolism; D053767:Glucagon-Like Peptide 2 / Q000378:metabolism*; D006801:Humans; D007408:Intestinal Absorption; D012778:Short Bowel Syndrome / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy
D015415:Biomarkers; D053767:Glucagon-Like Peptide 2